ArticleTechniques in coloproctology2025
Prediction tool for early identification of patients at risk of Crohn's disease in perianal fistulas and abscesses (PREFAB): Analysis of a prospective pilot study at a non-academic, teaching centre in the Netherlands.
Article in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to identify patients at risk of Crohn's disease (CD) when presenting with perianal disease and to prospectively identify clinical characteristics ('red flags') associated with CD.
methodsAll consecutive patients ≥ 16 years presenting with a perianal abscess (PAA)/fistula (PAF) between January and December 2022 were prospectively included. Faecal calprotectin (FCP) was measured in all patients, and patients were screened for potential red flags associated with CD by the use of a perianal red flags index (pRFI)-questionnaire. Colonoscopy was performed when FCP ≥ 150 mcg/g.
resultsOverall, 115 patients were included (median age 38 years; IQR 28-53), 55 with PAA (48%) and 60 with PAF (52%). In total, 19 patients had FCP levels ≥ 150 mcg/g (median 381 mcg/g; IQR 191-1040), and were referred for colonoscopy, of which 10 were diagnosed with CD (9% of all patients; 17% of patients with PAF). Of all patients with PAF < 40 years, 29% were diagnosed with CD (9/31). During a minimal follow-up of 2 years, two colonoscopies were performed in patients with clinical suspicion for CD, demonstrating CD in 1 patient, resulting in a total of 11/115 patients with CD (10%), all presenting with PAF (18% of all patients with PAF). Univariate analysis showed that young age (< 40 years; odds ratio [OR] 4.9; 95% confidence interval [CI] 1.0-23.6), abdominal pains (OR 4.8; 95% CI 1.2-19.1), rectal bleeding (OR 4.3; 95% CI 1.2-15.6), fatigue (OR 3.9; 95% CI 1.1-14.4), multiple external (OR 6.0; 95% CI 1.5-24.6)/internal fistula openings (OR 61.2; 95% CI 9.8-383.4), fissures (OR 4.4; 95% CI 1.1-17.2), and proctitis (OR 22.9; 95% CI 1.9-277.5) increased the likelihood of having CD.
conclusionWith FCP-based screening for CD, approximately one in six patients with PAF, and even one in three patients with PAF < 40 years were diagnosed with CD. Therefore, FCP measurement is suggested in all patients with PAF, especially when they are < 40 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.